AI Engines For more Details: Perplexity Kagi Labs You
Epilepsy: Carbamazepine is one of the first-line treatments for various types of epilepsy, including focal seizures (formerly known as partial seizures) and generalized tonic-clonic seizures (formerly known as grand mal seizures). It works by stabilizing neuronal membranes, reducing the excessive electrical activity that leads to seizures.
Trigeminal Neuralgia: Carbamazepine is also commonly used to treat trigeminal neuralgia, a type of neuropathic pain characterized by severe facial pain along the trigeminal nerve distribution. By suppressing abnormal nerve firing, carbamazepine can help alleviate the sharp, stabbing pain associated with this condition.
Bipolar Disorder: Carbamazepine is sometimes used as a mood stabilizer in the management of bipolar disorder, particularly in cases where lithium or other mood stabilizers are ineffective or poorly tolerated. It can help prevent manic and depressive episodes and stabilize mood fluctuations in individuals with bipolar disorder.
Other Neuropathic Pain Conditions: In addition to trigeminal neuralgia, carbamazepine may be prescribed off-label to manage other neuropathic pain conditions, such as diabetic neuropathy, postherpetic neuralgia, and radiculopathy (nerve root pain). Its mechanism of action in neuropathic pain involves modulation of voltage-gated sodium channels in the nervous system.
Safety Considerations: While generally effective, carbamazepine can cause a range of side effects, including dizziness, drowsiness, nausea, vomiting, blurred vision, ataxia, and cognitive impairment. Serious adverse effects may occur, such as severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), hematological abnormalities (e.g., leukopenia, thrombocytopenia), and liver toxicity. Regular monitoring of blood counts and liver function tests is often recommended during carbamazepine therapy.
Drug Interactions: Carbamazepine has a significant potential for drug interactions due to its induction of hepatic enzymes, particularly cytochrome P450 enzymes. It can accelerate the metabolism of many other medications, reducing their efficacy and necessitating dose adjustments. Conversely, certain drugs may inhibit the metabolism of carbamazepine, leading to increased plasma levels and potential toxicity.
Pregnancy and Breastfeeding: Carbamazepine may pose risks to pregnant individuals and their developing fetuses, including an increased risk of congenital malformations (e.g., neural tube defects) and developmental delays. However, the decision to continue or discontinue carbamazepine therapy during pregnancy should be carefully weighed based on individual clinical circumstances and the potential risks and benefits. Carbamazepine is excreted in breast milk and may cause adverse effects in breastfeeding infants.
Dosage and Administration: Carbamazepine is typically taken orally in tablet or liquid form. The dosage regimen varies depending on the patient's age, weight, medical condition, and response to treatment. It is important to follow the prescribing healthcare professional's instructions and undergo regular monitoring to ensure optimal therapeutic outcomes and minimize the risk of adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.5 | -0.03 |
| Allergies | 7.5 | 4.3 | 0.74 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 8.3 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.5 | 1.87 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.4 | 0.91 |
| Atherosclerosis | 2.7 | 2.4 | 0.13 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.9 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 2.9 | -2.22 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 4.3 | -0.19 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.4 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.9 | 2.8 | 2.18 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12.1 | 14.9 | -0.23 |
| Crohn's Disease | 10.4 | 6.9 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.6 | 11.1 | 0.23 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.5 | 2.8 | 0.61 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 2.5 | 0.56 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5.4 | 2.4 | 1.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.8 | -0.17 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 4.1 | 0.3 | 12.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.9 | 12.1 | -0.11 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 10 | 6.4 | 0.56 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 9.2 | 5.9 | 0.56 |
| Long COVID | 8.7 | 9.3 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 9.5 | 9.6 | -0.01 |
| Mood Disorders | 13.5 | 9 | 0.5 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9 | 7 | 0.29 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.8 | 10.1 | 0.27 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.6 | 8.3 | 0.28 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.4 | 4 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 10.5 | 9 | 0.17 |
| Ulcerative colitis | 7 | 8.8 | -0.26 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
